P. Satyanarayana, Priyanka Agrahari


Hyperglycemia is the main feature of diabetes mellitus type 2 which cause the non enzymatic glycation of haemoglobin and influence the lipid metabolism. In this comparative study, plasma of 150 Subjects (50-poor control (HbA1c >7%), 50-good control (HbA1c <7%) and 50-Controls) were analyzed for blood glucose and HbA1c and serum for lipid profile. A significant increase in TC, TG, VLDL-C and LDL-C concentrations were found in poor control than good control and Controls (‘p’= 0.000) except HDL-C level which is not significantly increase in poor control (‘p’= 0.132). In poor control HbA1c show the positive correlation with TC, TG, VLDL-C (‘p’= <0.05) except HDL-C (‘p’= 0.133). In good control HbA1c show significant correlation with lipid profile but less significant than poor control. This dual biomarker- HbA1c, glycemic control as well as lipid profile can be used for screening and early diagnosis of dyslipidemia.


Glycated hemoglobin, Dyslipidemia, Diabetes mellitus

Full Text:



American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35:S64–71.

Ronald Kahn C, George L King. et al. Joslins diabetes mellitus -14th edition (New York, Lippincott Williams & wilkins, 2005, 331-338.

Joslin‟s Diabetes Mellitus 14th Ed Lippincott Williams & Wilkins Chapter 33: Genearl approach to the treatment of diabetes mellitus.

Amos Af, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year DiabetMed, 1997; 14(5):1-85.

Ayaz K M, Ravindra M, Vivek R, Joshi P, Gopalakrishna Bhat. A study on APO B100/APO A-I Ratio in uncontrolled Type 2 diabetes mellitus. Int.J.Appl.Biol.Pharma.Tech. 2011;2(1):379-84.

Trinder, P. Ann. Clin. Biochem . 6(24) 1969

Trivelli ,L.A.,Ranney,H.M.,et al.,New Eng.J.Med.284,353 (1971).

Erba Mannheim CHOD-PAP end point for the in vitro quantitative determination of Cholesterol in human serum and plasma.

Erba Mannheim GPO – Trinder for the in vitro quantitative determination of Triglycerides in human serum and plasma.

Erba Mannheim HDL Direct for the in vitro quantitative determination of HDL Cholesterol in human serum.

Friedwald WT, Levy RI, Fredrichseon DS. Estimation of the concentration of low density lipoproteins in plasma without ultracentrifuge. Clin Chem., 1972;18: 499-502.

Rosmee and Shyamal Koley, Association of HbA1c with Lipid profiles in patients with Type 2 diabetes mellitus, International Journal of Biomedical Research 2016; 7(3): 139-143.,ISSN: 0976-9633 (Online); 2455-0566 (Print) ,Journal DOI: 10.7439/ijbr

Klisic A, Kavaric N, Jovanovic M, Zvrko E, Skerovic V, Scepanovic A, et al. Association between unfavorable lipid profile and glycemic control in patients with type 2 diabetes mellitus. J Res Med Sci 2017;22:122.

Joslin‘s Diabetes Mellitus 14th Ed Lippincott Williams & Wilkins Chapter 33: General approach to the treatment of diabetes mellitus.

Gosavi S, Karande S, Raut K. HbA1c: A Marker for Severity of Acute Myocardial Infarction. IAIM, 2016; 3(5): 89-93.

A.Valarmathi, Lalbahadur Sastri. Glycated hemoglobin as a marker of dyslipidemia in Type 2 diabetes mellitus patients in a tertiary care hospital. IAIM, 2017; 4(2): 21-25.

Sherwani et al. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker Insights 2016:11 95–104 doi: 10.4137/BMI.S38440.

Boden G; Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 1997; 46(1):47-55.

Mgonda YM, Ramaiya KL, Swai AB, McLarty DG, Alberti KG; Insulin resistance and hypertension in non obese Africans in Tanzania. Hypertension, 1998; 31(1):114-118.

Carmena R; High risk of lipoprotein dysfunction in type 2 diabetes mellitus. Rev Esp Cardiol Supl., 2008; 8 (supl C): 18C-24C.

Isezuo SA, Badung SLH, Aimls Fimls (2003) Comparative analysis of lipid profiles among Patients with type 2 diabetes mellitus, Hypertension and concurrent type 2 diabetes, and hypertension: A view of metabolic syndrome, Journal of the national medical association, 95: 328-334.

Sahay BK (2005) Diabetes Mellituse.Diabetology.18: 1042- 1081.

Joslin‟s Diabetes Mellitus 14th Ed. Lippincott Williams & Wilkins Chapter 33: Pathophysiology and treatment of lipid disorders in diabetes, pp. 567-571.


  • There are currently no refbacks.